Tagraxofusp Targets Multiple Myeloma Plasmacytoid Dendritic Cells

Tagraxofusp is a novel targeted therapy against CD123 that is FDA-approved for treatment of blastic plasmacytoid dendritic cell neoplasms. A phase 1/2 clinical trial of tagraxofusp was recently completed that showed preliminary safety and efficacy when used in combination with pomalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma.

Arghya Ray, PhD and colleagues analyzed bone marrow and peripheral blood samples from patients with multiple myeloma receiving treatment with tagraxofusp and observed a reduction in the frequency of viable plasmacytoid dendritic cells (pDCs) from an average of 2% at the time of screening to 0.75% following treatment, validating the target specificity of the drug.